Breast Cancer Cells Charlotte NC

Breast cancer patients with isolated tumor cells or tiny "micrometastases" in the lymph nodes benefit from adjuvant treatment, such as post-surgical chemotherapy or hormonal therapy, a new study finds.

John Burnett Holt
(704) 384-4814
200 Hawthorne Lane
Charlotte, NC
Specialty
Hematology

Data Provided by:
Herman Allen Godwin Jr, MD
(704) 841-1444
PO Box 32861
Charlotte, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Bowman Gray Sch Of Med Of Wake Forest Univ, Winston-Salem Nc 27157
Graduation Year: 1963

Data Provided by:
Jonathan Cyrus Salo, MD
(704) 355-3809
PO Box 32861
Charlotte, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Ca, San Francisco, Sch Of Med, San Francisco Ca 94143
Graduation Year: 1985

Data Provided by:
Dr.James Hall
(704) 446-1545
1025 Morehead Medical Dr # 600
Charlotte, NC
Gender
M
Education
Medical School: Med Univ Of Sc Coll Of Med
Year of Graduation: 1974
Speciality
Oncologist
General Information
Hospital: Carolinas Medical Center
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 3, reviews.

Data Provided by:
Anthony Lawrence Asher, MD
(704) 376-1605
Carolina Neurosurgery and Spine Asociates 225 Baldwin Road
Charlotte, NC
Specialties
Neurological Surgery, Surgical Oncology
Gender
Male
Education
Medical School: Wayne State Univ Sch Of Med, Detroit Mi 48201
Graduation Year: 1982

Data Provided by:
Wendy Graham Brick
(704) 302-8000
1025 Morehead Medical Dr
Charlotte, NC
Specialty
Hematology / Oncology

Data Provided by:
Mark Jeffrey Mogul, MD
(704) 384-1900
1712 E 4th St
Charlotte, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Suny-Hlth Sci Ctr At Syracuse, Coll Of Med, Syracuse Ny 13210
Graduation Year: 1987

Data Provided by:
Dr.Guilherme Cantuaria
(704) 384-8200
200 Hawthorne Lane
Charlotte, NC
Gender
M
Education
Medical School: Fund Univ De Brasilia, Fac De Cien, Brasilia-Df
Year of Graduation: 1992
Speciality
Oncologist
General Information
Accepting New Patients: Yes
RateMD Rating
3.0, out of 5 based on 2, reviews.

Data Provided by:
Heather Dawn Pacholke
(704) 333-7376
200 Queens Rd
Charlotte, NC
Specialty
Radiation Oncology

Data Provided by:
Avinash Shah, MD
(704) 372-3126
2115 E 7th St Ste 102
Charlotte, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Nairobi, Coll Of Hlth Sci, Nairobi, Kenya
Graduation Year: 1978

Data Provided by:
Data Provided by:

Breast Cancer Cells

Provided By:

Breast cancer patients with isolated tumor cells or tiny "micrometastases" in the lymph nodes benefit from adjuvant treatment, such as post-surgical chemotherapy or hormonal therapy, a new study finds.

Until now, many doctors doubted that the presence of micrometastases or isolated tumor cells affected long-term recovery, said Dr. Vivianne Tjan-Heijnen, head of the division of medical oncology at Maastricht University Medical Center in the Netherlands, the lead author of the study.

So these patients often are not offered adjuvant therapy after they undergo breast cancer surgery. But the results of her team's study, published in the Aug. 13 issue of the New England Journal of Medicine, suggest they should be.

Micrometastases, which are too small to be seen on standard screening or diagnostic tests, range from 0.2 to 2.0 millimeters in size. Isolated tumor cells or tumor cell groups are even tinier, less than 0.2 millimeters, said Tjan-Heijnen.

To assess the value of additional treatments of chemo or other adjuvant methods, Tjan-Heijnen and her colleagues followed 2,707 women treated surgically for early-stage breast cancer. They were divided into three groups. The first group included 856 women diagnosed with breast cancer whose sentinel node -- the first node the breast tissue drains into -- was negative and cancer-cell free, who didn't get additional treatment. The second group included 856 women diagnosed with breast cancer with cancer cells found in the nodes, but who didn't get additional treatment. The third group included 995 patients with cancer cells found in the nodes who did get additional treatment.

The additional treatment included chemotherapy (such as taxanes), endocrine therapy (such as tamoxifen or aromatase inhibitors), or systemic therapy (both chemo and endocrine).

The researchers followed the women for a median of 5.1 years (half followed longer, and half for less time) to see if the extra therapy reduced cancer recurrence and increased disease-free survival. They associated the tiny metastases and isolated tumor cells with an absolute decline in five-year disease-free survival of 10 percent. In other words, those with the tiny cancer cells present who are treated with additional therapy had a nearly 10 percent improvement in disease-free survival at five years, they found.

"So, five years after the diagnosis of every 100 patients with micrometastases or isolated tumor cells, 10 more will have a disease event compared with 100 patients with comparable primary tumor characteristics who did not have metastases in the axillary nodes," Tjan-Heijnen said.

The study proves that the micrometastases and the isolated tumor cells are important considerations when evaluating the prognosis, she said.

Cancer specialists have debated how to treat a patient with these small metastases and isolated tumor cells, said Dr. Minetta Liu, director of translational breast cancer research at the Georgetown University Lombardi Comprehensive Cancer Center in Washington, D.C.

The study results suggest that "looking for these cells may be another tool to determine how likely a recurrence is," she said. But more study is needed to validate the findings, she added.

Dr. Hannah Linden, a medical oncologist and associate professor of medicine at the University of Washington School of Medicine in Seattle, said the study results could change current practice. "If these findings are true, they will influence decision making significantly, and help us know which patients really 'need' chemo to give them an advantage in reducing the risk that the tumor recurs," she said.

More information

To learn more about adjuvant therapy for breast cancer, visit the U.S. National Cancer Institute.

SOURCES: Vivianne Tjan-Heijnen, M.D., Ph.D., head of medical oncology division, Maastricht University Medical Center, the Netherlands; Minetta Liu, director of translational breast cancer research, Georgetown University Lombardi Comprehensive Cancer Center, Washington, D.C.; Hannah Linden, M.D., medical oncologist and associate professor of medicine, University of Washington School of Medicine, and joint associate member, Fred Hutchinson Cancer Research Center, Seattle; Aug. 13, 2009, The New England Journal of Medicine

Author: By Kathleen Doheny
HealthDay Reporter

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com